RecruitingPhase 2NCT06461182

Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma

Ga-68-CXCR4 PET/CT in Detecting, Evaluating Response to Treatment, and Monitoring Risk of Aggressiveness of Indolent B-cell Lymphoma

Sponsor

Koo Foundation Sun Yat-Sen Cancer Center

Enrollment

15 participants

Start Date

Apr 29, 2024

Study Type

INTERVENTIONAL

Conditions

Indolent B-Cell Non-Hodgkin Lymphoma

Summary

This study explores the efficacy of Ga-68-PentixaFor PET/CT in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent B-cell lymphoma. The background introduces CXCR4 and discusses its role in cancer research. Currently, FDG-PET is the primary imaging tool for lymphoma staging, but it lacks diagnostic accuracy for low-grade lymphomas. Ga-68-PentixaFor PET demonstrates promising detection capabilities across various lymphomas, suggesting its potential as a superior imaging modality for low-grade lymphomas.

Eligibility

Min Age: 20 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This study evaluates a new PET scan tracer called Ga-68-CXCR4 as an imaging tool for detecting slow-growing (indolent) B-cell lymphomas, comparing it to the standard FDG PET scan to see if it provides better or complementary information. **You may be eligible if...** - You have been diagnosed with an indolent B-cell lymphoma (such as marginal zone lymphoma, Waldenström macroglobulinemia, CLL/SLL, or mantle cell lymphoma) - You are scheduled for or have recently had a standard FDG PET scan for staging, treatment response, or follow-up - You can lie flat for at least 30 minutes - You have an ECOG performance score of 0–2 **You may NOT be eligible if...** - You are pregnant - You have severe kidney problems - You have a known allergy to radioactive tracers - You have another active cancer besides lymphoma - You have severe medical conditions or mental disorders preventing participation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.